October 15, 2007
Prospector
Profile
07.1427
 
Senesco Technologies, Inc. NAICS 541710
303 George Street, Suite 420 New Brunswick, NJ 08901 Description Biotechnology
(732) 296-8400 Employees 24
http://www.senesco.com/ Revenue (mil) 0.3000
  Income (mil) -3.2510
  Assets (mil) 3.3210
  Liability (mil) 0.6320
  (for the year ended 2007-06-30)
 
Category: Audit Concerns
 
Event: Goldstein Golub Kessler LLP expressed doubts on the ability of Senesco Technologies, Inc. to continue as a going concern after auditing its financial statements. The auditor points out that the Company has incurred recurring losses from operations and has an accumulated deficit of $25,621,540 as of June 30, 2007.
 
Intellectual Property: The Company has 15 issued patents from the United States Patent and Trademark Office (PTO) and 12 issued patents from foreign countries including 7 from New Zealand, 2 from Australia, 1 from Mexico and 1 from Hong Kong. In addition, the Company has a wide variety of patent applications, including divisional applications and continuations-in-part, in process with the U.S. PTO and internationally. The Company intends to continue its strategy of enhancing these new patent applications through the addition of data as it is collected. [SEC Filing 10-K 09-28-07]
 
Description: The Company engages in the research and development of genetic technologies for commercial agriculture and to treat medical conditions in humans.
 
Officers: Ruedi Stalder (Chair); Bruce C. Galton (Pres. & CEO); Joel Brooks (CFO); John E. Thompson (EVP, Chief Scientific Officer & Dir.); Christopher Forbes (Dir.); Thomas C. Quick (Dir.); David Rector (Dir.); Jack Van Huls (Dir.); John Braca (Dir.)
 
Auditor: Goldstein Golub Kessler LLP
 
Securities: Common Stock-Symbol SNT; AMEX; 17,473,694 common shares outstanding as of September 15, 2007.
 
 
 
return to main page